Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Physiological Testosterone Replacement Does Not Raise Heart Attack Risk, Provided Hematocrit Stays Below 54%
Fishtown Medicine•6 min read

Physiological Testosterone Replacement Does Not Raise Heart Attack Risk, Provided Hematocrit Stays Below 54%

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 7, 2026
On This Page
  • What Did the TRAVERSE Trial Prove About Heart Attacks and Strokes?
  • Which Secondary Safety Signals in TRAVERSE Still Require Close Monitoring?
  • Why Does TRT Raise Hematocrit, and How Do Routes Compare?
  • How Does Fishtown Medicine Confirm Low Testosterone and Monitor Safety?
  • 1. Accurate Diagnosis and Reversible Root Causes
  • 2. ApoB, Blood Pressure, Hematocrit, and PSA Monitoring
  • Guidance From the Clinic
  • Actionable Steps in Philly
  • Common Questions
  • Is TRT safe for the heart?
  • Why did the FDA update testosterone labels in 2025?
  • Does TRT cause blood clots?
  • What happens if my hematocrit reaches 54% on TRT?
  • Does subcutaneous or split-dose TRT prevent high hematocrit?
  • Will TRT cause prostate cancer?
  • Deep Questions
  • Why does testosterone raise hematocrit while enclomiphene and clomiphene rarely do?
  • Why is routine blood donation not a standalone fix for high hematocrit on TRT?
  • Can weight loss or sleep extension reverse low testosterone without medication?
  • Does CPAP therapy for sleep apnea raise testosterone on its own?
  • What is the prostate saturation model?
  • Scientific References
  • Related at Fishtown Medicine

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

Physiologic TRT did not increase major heart attacks, strokes, or cardiovascular death (7.0% vs 7.3%, HR 0.96) in the 5,246-patient TRAVERSE randomized trial (NEJM 2023), nor did it increase prostate cancer when baseline PSA was 3.0 ng/mL or lower. However, TRAVERSE showed slightly higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury (2.3% vs 1.5%), which is why we monitor hematocrit (< 54%), blood pressure, and ApoB on a strict schedule.

Physiologic testosterone replacement therapy (TRT) did not increase major heart attacks, strokes, or heart deaths (7.0% vs 7.3%, HR 0.96) in the landmark 5,246-patient TRAVERSE trial. Safe treatment still requires active tracking for high hematocrit (>= 54%), blood pressure rises, atrial fibrillation, and venous clots.

TL;DR - Your Next Steps

  1. Know what TRAVERSE proved (NEJM 2023): In 5,246 men aged 45 to 80 with two fasting morning testosterone levels below 300 ng/dL and high heart risk, daily testosterone gel did not raise 3-point MACE (HR 0.96) or high-grade prostate cancer (0.19% vs 0.12%).
  2. Respect the secondary safety signals: Testosterone showed higher rates of atrial fibrillation (3.5% vs 2.4%), nonfatal arrhythmias (5.2% vs 3.3%), pulmonary embolism (0.9% vs 0.5%), and blood pressure increases. In 2025, the FDA removed the boxed heart-attack warning while adding a class-wide blood-pressure warning.
  3. Keep hematocrit strictly below 54%: Testosterone stimulates erythropoietin (EPO) and suppresses hepcidin. Large biweekly IM injections (200 mg every 2 weeks) trigger more red cell thickening (8% vs 1% on weekly 100 mg IM). If hematocrit hits >= 54%, we hold or lower the dose and screen for sleep apnea.
  4. Fix reversible root causes first: Weight loss (+72 to +207 ng/dL), sleeping more than 5 hours a night (10 to 15% T difference), and treating severe sleep apnea protect both your heart and your hormone levels.

TRT vs. Enclomiphene & Clomiphene: Fertility, TRAVERSE Safety, and Hematocrit Blueprint

What Did the TRAVERSE Trial Prove About Heart Attacks and Strokes?

The TRAVERSE randomized trial (Lincoff et al., NEJM 2023) proved that physiologic testosterone replacement does not increase the combined risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke (7.0% vs 7.3%, HR 0.96, 95% CI 0.78 to 1.17).

For a decade, fears about testosterone and heart attacks rested on two flawed observational studies from 2013 and 2014. Those papers lacked proper control groups or mixed replacement dosing with steroid abuse. To settle the question, the FDA mandated TRAVERSE. The trial enrolled 5,246 men aged 45 to 80 with hypogonadal symptoms, two fasting morning testosterone readings below 300 ng/dL, and pre-existing heart disease or multiple cardiac risk factors.

Over a mean treatment time of 21.7 months and 33.0 months of follow-up using daily 1.62% testosterone gel titrated between 350 and 750 ng/dL:

  • Primary 3-point MACE: Occurred in 182 men (7.0%) on testosterone versus 190 men (7.3%) on placebo (p < 0.001 for non-inferiority).
  • Prostate cancer safety (Bhasin et al., JAMA Netw Open 2023): Among men screened at baseline with PSA <= 3.0 ng/mL, total prostate cancer (0.46% vs 0.42%, HR 1.07) and high-grade prostate cancer (0.19% vs 0.12%, HR 1.62) were nearly identical between testosterone and placebo, with no excess acute urinary retention.
  • 2025 FDA label update: Based on TRAVERSE and ambulatory blood-pressure trials, the FDA removed the boxed warning for major heart events in 2025 while adding a class-wide warning for modest blood-pressure rises.

Which Secondary Safety Signals in TRAVERSE Still Require Close Monitoring?

While heart attacks and strokes did not increase in TRAVERSE, men assigned to testosterone had higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury (2.3% vs 1.5%).

Good internal medicine examines the entire clinical table alongside the primary endpoint:

TRAVERSE Outcome (n = 5,246)Testosterone Gel (n = 2,601)Placebo Gel (n = 2,603)Clinical Takeaway at Fishtown Medicine
Primary 3-Component MACE7.0% (182)7.3% (190)Non-inferior (HR 0.96); no excess MI or stroke.
Nonfatal Arrhythmias5.2% (134)3.3% (87)Statistically higher (p = 0.001); check baseline rhythm and electrolytes.
Atrial Fibrillation3.5% (91)2.4% (63)Higher (p = 0.02); evaluate palpitations, alcohol intake, and sleep apnea.
Pulmonary Embolism (PE)0.9% (24)0.5% (12)Use caution in men with prior unprovoked VTE or thrombophilia; keep hematocrit < 54%.
Acute Kidney Injury (AKI)2.3% (60)1.5% (40)Higher (p = 0.04); monitor blood pressure, hydration, and creatinine (CMP).
High-Grade Prostate Cancer0.19% (5)0.12% (3)No significant difference (HR 1.62) when baseline PSA <= 3.0 ng/mL.

Why Does TRT Raise Hematocrit, and How Do Routes Compare?

Testosterone raises red blood cell mass (hematocrit) by stimulating kidney erythropoietin (EPO) and suppressing the iron-regulatory hormone hepcidin (Bachman et al., 2014), which increases iron absorption and red cell production.

Both the Endocrine Society and the American Urological Association (AUA) define hematocrit >= 54% as the action threshold for secondary erythrocytosis on TRT. How you take testosterone strongly shapes how high your hematocrit climbs:

  • Large biweekly intramuscular (IM) boluses carry the highest risk: In head-to-head dosing studies (El-Khatib et al., 2022), injecting 200 mg IM every 2 weeks pushed hematocrit above 54% in 8% of men, compared with 1% of men taking 100 mg IM once weekly.
  • Injectable vs. transdermal vs. subcutaneous (SC): Across randomized trials (Nackeeran et al., 2022), intramuscular testosterone raised mean hematocrit by +4.0 percentage points compared with +3.0 points on transdermal gel. Weekly subcutaneous (SC) testosterone enanthate shows slightly lower post-therapy hematocrit than IM cypionate (Choi et al., 2022), though 4.2% of men on weekly SC autoinjectors still reach >= 55% - meaning split dosing or SC injections lower peak exposure without replacing routine blood counts.
  • Oral SERMs (clomiphene / enclomiphene) rarely thicken the blood: In direct clinical comparisons (Wheeler et al., 2017), oral clomiphene raised mean hematocrit by +0.6 percentage points versus +3.0 points on TRT.
  • Why we fix the dose and sleep apnea first: Therapeutic phlebotomy temporarily lowers hematocrit, but repeated blood donations without lowering the testosterone dose deplete ferritin and cause iron deficiency while EPO stays high. When hematocrit nears 52 to 54%, we reduce or split the dose, consider switching to transdermal gel or enclomiphene, and screen for untreated sleep apnea (Lundy et al., 2020).

How Does Fishtown Medicine Confirm Low Testosterone and Monitor Safety?

We confirm true hypogonadism with two fasting morning blood draws (7:00 to 10:00 AM) including SHBG and equilibrium-dialysis free testosterone, address reversible metabolic causes first, and monitor ApoB, hematocrit, blood pressure, and PSA on a set schedule.

1. Accurate Diagnosis and Reversible Root Causes

Many men with a borderline total testosterone (250 to 320 ng/dL) have low SHBG driven by insulin resistance and visceral fat, while their free testosterone is normal. Before starting lifelong hormone therapy, we measure:

  • Two fasting morning (7:00 to 10:00 AM) total testosterone levels alongside SHBG and free testosterone by equilibrium dialysis or calculated Vermeulen equation (avoiding inaccurate direct analog tests).
  • Pituitary and reversible drivers: LH, FSH, prolactin, ferritin, and thyroid function (pituitary MRI if total T < 150 ng/dL). Weight loss raises total testosterone by +72 ng/dL with diet and +207 ng/dL after bariatric surgery (Anawalt, JAMA 2026), and extending sleep from 5 hours to 8 hours prevents a 10 to 15% daytime testosterone drop (Leproult, JAMA 2011).

2. ApoB, Blood Pressure, Hematocrit, and PSA Monitoring

  • ApoB (Apolipoprotein B): Counts every atherogenic lipoprotein particle so we protect your arteries while optimizing your hormones.
  • Home blood pressure: Because TRT can raise systolic blood pressure by 1 to 4 mmHg via sodium and fluid retention, we target < 120/80 mmHg at home.
  • CBC (Hematocrit) and PSA: Checked at baseline, 3 months, 6 months, and every 6 months thereafter. If hematocrit reaches >= 54%, we hold therapy or reduce the dose right away. If PSA rises by more than 1.4 ng/mL in the first year or crosses 4.0 ng/mL, we repeat the draw and coordinate a urology visit.

Guidance From the Clinic

"I cannot promise zero risk on any hormone, and I will never oversell it. What TRAVERSE gave us is clear randomized boundaries: keeping testosterone in a normal physiologic range does not cause heart attacks, provided we respect blood pressure, rhythm, clot history, and the 54% hematocrit ceiling."

  • Dr. Ash

Actionable Steps in Philly

Make hormone optimization safe and data-driven.

  1. Get a complete morning baseline: Draw two fasting morning (7:00 to 10:00 AM) panels with total testosterone, SHBG, equilibrium-dialysis or calculated free testosterone, LH, FSH, prolactin, CBC (hematocrit), CMP, PSA, and ApoB.
  2. Screen for sleep apnea before starting TRT: If you snore, wake unrefreshed, or have high blood pressure, run a home sleep study first; untreated severe OSA accelerates erythrocytosis (hematocrit >= 54%) on TRT.
  3. Avoid 200 mg biweekly roller-coaster dosing: Use smaller weekly or twice-weekly doses (or daily transdermal gel) titrated to the mid-normal physiologic range (450 to 750 ng/dL).

Related Articles:

  • Men's Hormone Health Overview
  • ApoB and Heart Health
  • Metabolic Health 101
  • Peptides: What's Approved, What's Gray Market, and What's Dangerous - testosterone is a well-studied FDA-approved hormone; this is the deeper context for the gray-market peptide ecosystem (BPC-157, TB-500, CJC-1295, MK-677) that is often pitched alongside TRT but has very different evidence behind it.

Scientific References

  1. Lincoff AM, Bhasin S, Flevaris P, et al. (2023). "Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE)." The New England Journal of Medicine, 389(2), 107-117.
  2. Bhasin S, Travison TG, Pencina KM, et al. (2023). "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial (TRAVERSE)." JAMA Network Open, 6(12), e2348692.
  3. Bachman E, Travison TG, Basaria S, et al. (2014). "Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: a randomized controlled trial." The Journals of Gerontology: Series A, 69(6), 725-735.
  4. El-Khatib FM, Huynh LM, Yafi FA, et al. (2022). "Subcutaneous and intramuscular testosterone therapy and secondary polycythemia." The Journal of Sexual Medicine.
  5. Nackeeran S, Kohn T, Gonzalez D, et al. (2022). "The Effect of Route of Testosterone on Hematocrit: A Systematic Review and Meta-Analysis of Randomized Clinical Trials." The Journal of Urology, 207(1), 44-51.
  6. Bhasin S, Brito JP, Cunningham GR, et al. (2018). "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744.

Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. He manages hormones with the safety standards of a hospitalist.

Related at Fishtown Medicine

  • Testosterone Replacement Therapy (TRT) - the clinical TRT approach with safety monitoring
  • TRT vs Enclomiphene - the choice between exogenous testosterone and endogenous stimulation
  • What Testosterone Does and Doesn't Do - realistic expectations on TRT outcomes
  • Men's Hormone Health - the full men's hormone landscape
  • Male Fertility - the male fertility workup and treatment options
  • Sleep Apnea and Testosterone - why OSA is a key reversible factor in low T and high hematocrit
  • Andropause Nutrition - the dietary inputs to men's hormonal health
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all". The right plan must be matched to your unique labs, physiology, and goals. Talk with Dr. Ash to see if this approach is right for you, particularly if you have chronic conditions or take prescription medications.
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Hormones

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Start Your Intake

Frequently Asked Questions

Common Questions

Yes, when dosed to normal physiologic levels in properly screened men. In the 5,246-patient TRAVERSE trial (NEJM 2023), testosterone replacement matched placebo for major heart events (7.0% vs 7.3%, HR 0.96). Because it showed higher rates of atrial fibrillation (3.5% vs 2.4%) and pulmonary embolism (0.9% vs 0.5%), active medical monitoring is essential.
Following the TRAVERSE cardiovascular outcome trial and dedicated ambulatory blood-pressure studies, the FDA removed the boxed warning for heart attack and stroke in 2025 while adding a consistent class-wide warning that testosterone products can raise blood pressure.
In TRAVERSE, pulmonary embolism occurred in 0.9% (24 men) on testosterone versus 0.5% (12 men) on placebo. We avoid TRT in men with recent unprovoked venous thromboembolism (VTE), screen carefully when clot risk factors exist, and keep hematocrit below 54%.
If on-treatment hematocrit reaches >= 54%, Endocrine Society and AUA guidelines recommend holding TRT until hematocrit returns to a safe level, screening for hypoxia or obstructive sleep apnea, and restarting at a lower dose or switching to a formulation with smaller peaks (such as transdermal gel or enclomiphene).
Splitting a large 200 mg biweekly IM dose into weekly 100 mg or twice-weekly smaller injections (or using subcutaneous SC injections) lowers peak testosterone levels and cuts the rate of hematocrit exceeding 54% (El-Khatib 2022; Choi 2022). Still, 4.2% of men on weekly SC testosterone reach >= 55%, so blood counts must be checked every 3 to 6 months.
No. In TRAVERSE (Bhasin et al., 2023), men screened with a baseline PSA <= 3.0 ng/mL had no significant increase in overall prostate cancer (0.46% vs 0.42%) or high-grade prostate cancer (0.19% vs 0.12%) over nearly 3 years. Testosterone remains contraindicated in men with active or prior prostate cancer without specialist clearance.

Deep-Dive Questions

Exogenous testosterone peaks stimulate kidney erythropoietin (EPO) and suppress liver hepcidin (Bachman et al., 2014), mobilizing iron into new red blood cells. Oral clomiphene and enclomiphene produce smoother endogenous testosterone pulses and mild liver estrogen-receptor effects, raising mean hematocrit by +0.6 percentage points compared with +3.0 to +4.0 points on TRT (Wheeler et al., 2017).
Repeated phlebotomy removes red blood cells and iron, driving down ferritin stores. When ferritin drops while testosterone keeps suppressing hepcidin and stimulating EPO, the bone marrow makes smaller, iron-deficient red cells. Patients can develop fatigue and restless legs without solving the hormone excess. Fixing the TRT dose and ruling out sleep apnea comes first.
Often, yes. In functional hypogonadism caused by metabolic syndrome, a low-calorie diet raises total testosterone by an average of +72 ng/dL, and bariatric surgery raises total testosterone by +207 ng/dL (Anawalt, JAMA 2026). Fixing chronic 5-hour sleep restriction also prevents a 10 to 15% drop in daytime testosterone (Leproult & Van Cauter, 2011).
Randomized trials and meta-analyses (Cignarelli et al., 2019; Clarke et al., 2020) show that CPAP alone does not reliably raise serum testosterone unless weight also drops. Still, treating obstructive sleep apnea before starting TRT matters because untreated severe OSA increases the risk of polycythemia (hematocrit >= 54%) and atrial fibrillation.
Proposed by Morgentaler and Traish (2009), the saturation model shows that prostate androgen receptors reach maximal binding around serum testosterone levels of 250 ng/dL. Raising testosterone from the 200s into the normal physiologic range (450 to 750 ng/dL) adds very little extra receptor stimulation inside the prostate, matching the neutral prostate cancer findings in TRAVERSE.

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Men's Hormone Optimization: Why Low T Is the Wrong Metric

Men's Hormone Optimization: Why Low T Is the Wrong Metric

Stop settling for "normal." Fishtown Medicine offers precision TRT and fertility-preserving strategies (HCG, Enclomiphene) for driven men in Philadelphia.

Read Deep Dive
Women's Hormone Health & BHRT Philadelphia

Women's Hormone Health & BHRT Philadelphia

Navigate perimenopause and menopause with confidence. We offer Bio-Identical Hormone Replacement Therapy (BHRT) aimed at symptom relief and long-term neuroprotection.

Read Deep Dive
Men's Hormone Health: Free Testosterone, Andropause, and Fertility

Men's Hormone Health: Free Testosterone, Andropause, and Fertility

Testosterone is not a solo act. Dr. Ash manages andropause with a focus on safety, fertility preservation, and cardiovascular health. A modern, systems-based approach.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share your symptoms, your cycle or lab history, and what has already been tried. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs